Janux Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Janux Therapeutics, Inc. (JANX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 11.13 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.58M shares, a 8.50% increase year-over-year.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 10.68M shares, a 7.72% increase year-over-year.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 9.91M shares, a 10.57% increase year-over-year.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 8.96M shares, a 21.45% increase year-over-year.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.27M shares, a 11.24% increase from fiscal 2024.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.23M shares, a 15.23% increase from fiscal 2023.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.01M shares, a 7.93% increase from fiscal 2022.
- Janux Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.42M shares, a 22.92% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.13M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 11.58M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 10.27M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 10.66M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 10.91M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 10.68M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 9.23M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 9.70M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 9.69M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 9.91M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 8.01M shares 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 8.54M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 9.11M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 8.96M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 7.42M shares 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 7.72M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 7.72M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 7.38M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 6.04M shares 10-K · filed 2023-03-10 | |||
| 2021-09-30 | 6.00M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 5.69M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 19.11M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 10.07M shares 10-K · filed 2022-03-18 | |||
| 2020-09-30 | 8.70M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 6.30M shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |